Identification and characterization of a new intermediate in the ribosylative inactivation pathway of rifampin by Mycobacterium smegmatis.
Mycobacterium smegmatis DSM 43756 inactivates rifampin by ribosylation. To study this process of rifampicin, all possible inactivated forms of the antibiotic were extracted and purified. Structural studies showed the presence of a new inactivation product, designated RIP-TAp(23-phosphoribosyl-rifampin). Formation of 23-(O-ADP-ribosyl)rifampin (RIP-TAs) is the first step, followed by removal of AMP to give rise to the newly identified compound. Lastly, dephosphorylation leads to formation of 23-ribosyl-rifampin (RIP-Mb). Feeding experiments with the ADP-ribosylated antibiotic obtained from the cell homogenates of an Escherichia coli strain carrying the cloned M. smegmatis gene confirmed this rifampin inactivation process.
Imai
T
T
Research Center for Pathogenic Fungi and Microbial Toxicoses, Chiba University, Japan.
Watanabe
K
K
Mikami
Y
Y
Yazawa
K
K
Ando
A
A
Nagata
Y
Y
Morisaki
N
N
Hashimoto
Y
Y
Furihata
K
K
Dabbs
E R
ER
D000904:Antibiotics, Antitubercular / Q000378:metabolism*; D008826:Microbial Sensitivity Tests; D008969:Molecular Sequence Data; D020102:Mycobacterium smegmatis / Q000378:metabolism*; D012266:Ribose / Q000378:metabolism*; D012293:Rifampin / Q000378:metabolism*
D000904:Antibiotics, Antitubercular; D012266:Ribose; D012293:Rifampin